TL-310 is a new taxane analogue that displays potent antitumor activity in a variety of human cancer cell lines and in human tumor xenografts. The mechanism of action of TL-310 includes microtubule polymerization, resulting in a block in the G2/M phase of the cell cycle and programmed cell death (apoptosis). In the 786-0 human renal carcinoma model, orally bioavailable TL-310 (80 mg/kg) was equally efficacious as IV administered paclitaxel or docetaxel. orally administered TL-310 consistently maintained excellent antitumor efficacy which was well below its maximum tolerated dose in mice. References:

纯度：≥98%

CAS：352697-38-2